Literature DB >> 17325874

Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.

Edward Chew, Robin Filshie, Andrew Wei.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325874     DOI: 10.1080/10428190600988010

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Bortezomib induced pulmonary toxicity: a case report and review of the literature.

Authors:  Burcin Saglam; Hakan Kalyon; Murat Ozbalak; Serdar Ornek; Siran Keske; Levent Tabak; Nahit Cakar; Handan Zeren; Saide Aytekin; Yasemin Bolukbasi; Burhan Ferhanoglu
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.

Authors:  Se Ryeon Lee; Seok Jin Kim; Yong Park; Hwa Jung Sung; Chul Won Choi; Byung Soo Kim
Journal:  Korean J Hematol       Date:  2010-09-30

3.  Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.

Authors:  Jingbo Li; Shuda Chen; Yinghong Hu; Jing Cai
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

4.  A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Terzah M Horton; John P Perentesis; Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Jennifer Ballard; Kathleen Adlard; Dianna S Howard; Franklin O Smith; Gaye Jenkins; Angelé Kelder; Gerrit J Schuurhuis; Jeffrey A Moscow
Journal:  Pediatr Blood Cancer       Date:  2014-06-29       Impact factor: 3.167

Review 5.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.